Vaginal Estrogen

Low-dose vaginal estrogen is estrogen applied directly in or around the vagina to treat genitourinary syndrome of menopause (GSM). It is available in forms such as creams, vaginal tablets or inserts, and rings. Unlike systemic estrogen used for hot flashes, low-dose vaginal estrogen is intended primarily to act locally, with very little estrogen reaching the bloodstream.

Improve vaginal dryness, burning and irritation, reduce pain with sexual activity, improve certain urinary symptoms, and help reduce recurrent urinary tract infections associated with menopause.

Low-dose vaginal estrogen has a substantial evidence base for treating genitourinary syndrome of menopause. Clinical guidelines and systematic reviews support its ability to improve vaginal dryness, irritation, and pain with sexual activity. Evidence also supports vaginal estrogen for reducing recurrent urinary tract infections in peri- and postmenopausal women. Low-dose vaginal estrogen produces much less systemic estrogen exposure than systemic hormone therapy and should not be assumed to have the same risk profile as estrogen pills, patches, gels, or sprays.

Vaginal estrogen can improve vaginal dryness, irritation, discomfort and pain with sexual activity caused by genitourinary syndrome of menopause. It may also improve certain menopause-related urinary symptoms and reduce recurrent urinary tract infections in appropriate women.

Low-dose vaginal estrogen should not be expected to treat hot flashes, night sweats, or other symptoms that require systemic treatment. It is not interchangeable with systemic menopausal hormone therapy.

Some improvement may occur within several weeks, although fuller improvement in vaginal and urinary symptoms can take longer and varies by individual.

Low-dose vaginal estrogen generally results in minimal systemic estrogen exposure and has a different safety profile from systemic hormone therapy. Local irritation, discharge, or spotting can occur. Unexplained vaginal bleeding should be medically evaluated. People with a history of estrogen-dependent cancer should discuss treatment options with their healthcare team. Current guidance allows consideration of low-dose vaginal estrogen in some breast cancer survivors when nonhormonal treatments are inadequate, using individualized shared decision-making.

Varies widely by formulation, pharmacy and insurance. Generic vaginal estrogen may cost roughly $20–$100+ per prescription fill without insurance, while some branded products can cost substantially more.